Article: PSMA Theranostics Is Poised to Change Prostate Cancer Landscape

[GregHouston]

May 22, 2021

Ashok Muthukrishnan, MD, MS

Targeted Therapies in Oncology, May 2021, Volume 10, Issue 7

With the recent success of lutetium Lu 177 dotatate (Lutathera) therapy for neuroendocrine tumor, the field of theranostics has come under a vivid spotlight in the last couple of years from oncologists, nuclear radiologists, cancer researchers, and the pharmaceutical industry. Although research focused on prostate-specific membrane antigen (PSMA) has been ongoing for almost 2 decades, the timing for the emergence of PSMA theranostics could not have been any better.

Ironically, the term PSMA is not specific to prostate cancer. It is in fact expressed in hepatocellular cancer and glioblastoma and some renal and colon cancers. PSMA is expressed up to 1000 times in prostate cancer, and its degree of expression seems to correlate with tumor dedifferentiation and the presence of metastases. The fact that current conventional imaging is woefully inadequate in detecting low-volume oligometastatic disease burden in prostate cancer makes PSMA targeting valuable from a diagnostic standpoint.

Read more here>>

targetedonc.com/view/psma-t...

[greatjohn]

fingers crossed for great results from this treatment and the ongoing trials.

[Bobcat64 in reply to greatjohn]

You rock big john hope your therapy is a big success

[greatjohn in reply to Bobcat64]

I am having some issues with platelets dropping and white cells and red cells dropping, but my doctor, Dr. Luke, just called me to say that they are in a place where it’s OK still at the point I am in the treatment. My second LU 177 injection is scheduled for June 24. Thanks so much for your kind words.

[GregHouston in reply to greatjohn]

That is fantastic! I know that must be a big relief for you. Congratulations on the great news. Wishing you much success on your treatment.

[greatjohn in reply to GregHouston]

Thanks 🥰

[6357axbz in reply to greatjohn]

Gj, what r your wbc and rbc counts?

[greatjohn in reply to 6357axbz]

WBC 2.4RBC 2.24

[6357axbz in reply to greatjohn]

Mine are about the same resulting from SBRT to some bone mets. MO not too worried at this point.

[greatjohn in reply to 6357axbz]

Thanks, wishing you the best!

[tango65]

It already changed it in a lot of countries. Let's hope we will get other PSMA PET/CTs (18F PYL) techniques and Lu 177 PSMA approved soon. We are years behind Europe, Israel, India, South Africa, Australia etc.

[Danish-patient]

PSMA used for diagnostics in PET scanners and for treatment coupled with Lutetium 177 is well established around the world and has been used for thousands of PCa patients for many years. The combined name theranostic was coined in Bad Berka in Germany. It’s what has kept me alive for the last five years. However, PSMA has not been invested by the pharma industry but by researchers in clinics in Europe. Therefore, it has not yet been officially approved by health authorities. But that is what will change the coming years - to the benefit of even more men around the world.

[EdBar]

Look for a big announcement (positive) the end of the moth on PSMA scans from the FDA.Findings of current Lutetium trial will be announced early June also positive.

Per Dr. Sartor during recent consultation.

Ed

[LeeLiam]

Are there any publicly traded stocks involved in Lu-177?